WO2015182765A1 - 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 - Google Patents
低分子化合物を用いた多能性幹細胞の心筋分化誘導法 Download PDFInfo
- Publication number
- WO2015182765A1 WO2015182765A1 PCT/JP2015/065643 JP2015065643W WO2015182765A1 WO 2015182765 A1 WO2015182765 A1 WO 2015182765A1 JP 2015065643 W JP2015065643 W JP 2015065643W WO 2015182765 A1 WO2015182765 A1 WO 2015182765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- atom
- inhibitor
- wnt signal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 92
- 230000004069 differentiation Effects 0.000 title claims abstract description 91
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 52
- 230000001939 inductive effect Effects 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title claims description 60
- 210000004027 cell Anatomy 0.000 claims abstract description 121
- 239000003112 inhibitor Substances 0.000 claims abstract description 81
- 239000012190 activator Substances 0.000 claims abstract description 59
- 229940122924 Src inhibitor Drugs 0.000 claims abstract description 30
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 26
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 26
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 94
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 81
- 125000005843 halogen group Chemical group 0.000 claims description 61
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 37
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 30
- FDVSOQRNTAPCHB-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical group C1CN(C)CCN1C1CCC(N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=C2)CC1 FDVSOQRNTAPCHB-UHFFFAOYSA-N 0.000 claims description 28
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 claims description 28
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 28
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical group C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000004434 sulfur atom Chemical group 0.000 claims description 23
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- 238000004114 suspension culture Methods 0.000 claims description 17
- 241000282693 Cercopithecidae Species 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 claims description 11
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
- LOGJQOUIVKBFGH-UHFFFAOYSA-N SU6656 Chemical compound C1CCCC(N2)=C1C=C2C=C1C(=O)NC2=CC=C(S(=O)(=O)N(C)C)C=C21 LOGJQOUIVKBFGH-UHFFFAOYSA-N 0.000 claims description 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 9
- 229960002584 gefitinib Drugs 0.000 claims description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 9
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 101000685824 Homo sapiens Probable RNA polymerase II nuclear localization protein SLC7A6OS Proteins 0.000 claims description 5
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 claims description 5
- 102100023136 Probable RNA polymerase II nuclear localization protein SLC7A6OS Human genes 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- ZGSXEXBYLJIOGF-BOPNQXPFSA-N iwr-1 Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2C(C=C3)CC3[C@@H]2C1=O ZGSXEXBYLJIOGF-BOPNQXPFSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 235000004252 protein component Nutrition 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 55
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 38
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 36
- 102000003923 Protein Kinase C Human genes 0.000 description 30
- 108090000315 Protein Kinase C Proteins 0.000 description 30
- 230000006698 induction Effects 0.000 description 28
- -1 KY03-I Chemical compound 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000003550 marker Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 239000005090 green fluorescent protein Substances 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 108010063503 Actinin Proteins 0.000 description 14
- 102000010825 Actinin Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 12
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 12
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 210000003716 mesoderm Anatomy 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 238000004115 adherent culture Methods 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000036390 resting membrane potential Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 229930182816 L-glutamine Natural products 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 230000001464 adherent effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- HVSJHHXUORMCGK-UONOGXRCSA-N Chromanol 293B Chemical compound C1=C(C#N)C=C2[C@H](N(C)S(=O)(=O)CC)[C@@H](O)C(C)(C)OC2=C1 HVSJHHXUORMCGK-UONOGXRCSA-N 0.000 description 7
- 101001133999 Homo sapiens Mesogenin-1 Proteins 0.000 description 7
- 102100034148 Mesogenin-1 Human genes 0.000 description 7
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 7
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003797 essential amino acid Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 0 C[C@](*)(C*(CCC(NS*C(C(N)=C)=*C(*1=CC1)=CC)=*)=C)C(*)=CC Chemical compound C[C@](*)(C*(CCC(NS*C(C(N)=C)=*C(*1=CC1)=CC)=*)=C)C(*)=CC 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 6
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 6
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 6
- 102000014021 KCNQ1 Potassium Channel Human genes 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 235000020776 essential amino acid Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- WMKLSFIAHMBOTP-UHFFFAOYSA-N 6-iodo-1,3-benzothiazol-2-amine Chemical compound C1=C(I)C=C2SC(N)=NC2=C1 WMKLSFIAHMBOTP-UHFFFAOYSA-N 0.000 description 5
- TUYZBSNOXFHLKL-UHFFFAOYSA-N Fc1cc(Cl)c(Cl)cc1Nc1ncnc2ccc(NC(=O)[C]Cl)cc12 Chemical compound Fc1cc(Cl)c(Cl)cc1Nc1ncnc2ccc(NC(=O)[C]Cl)cc12 TUYZBSNOXFHLKL-UHFFFAOYSA-N 0.000 description 5
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 5
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 5
- 230000036982 action potential Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940121647 egfr inhibitor Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 101001032038 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Proteins 0.000 description 4
- 102100038718 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Human genes 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- BQCNSTFWSKOWMA-GORDUTHDSA-N 2,5-dihydroxycinnamic acid methyl ester Chemical compound COC(=O)\C=C\C1=CC(O)=CC=C1O BQCNSTFWSKOWMA-GORDUTHDSA-N 0.000 description 3
- DNOKYISWMVFYFA-UHFFFAOYSA-N 6,7-dimethoxy-n-(4-phenylmethoxyphenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1)=CC=C1OCC1=CC=CC=C1 DNOKYISWMVFYFA-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 description 3
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 3
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 3
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- FQCPPVRJPILDIK-UHFFFAOYSA-N chembl126077 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=CC=C21 FQCPPVRJPILDIK-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 3
- 229960002993 ingenol mebutate Drugs 0.000 description 3
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- LUZOFMGZMUZSSK-LRDDRELGSA-N (-)-indolactam V Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-LRDDRELGSA-N 0.000 description 2
- USIFVFMNOLGPNL-UHFFFAOYSA-N (4-iodophenyl)thiourea Chemical compound NC(=S)NC1=CC=C(I)C=C1 USIFVFMNOLGPNL-UHFFFAOYSA-N 0.000 description 2
- XSHQBIXMLULFEV-UHFFFAOYSA-N 1-NA-PP1 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1C1=CC=CC2=CC=CC=C12 XSHQBIXMLULFEV-UHFFFAOYSA-N 0.000 description 2
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 2
- LHHKQWQTBCTDQM-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(CCC(O)=O)C=C1OC LHHKQWQTBCTDQM-UHFFFAOYSA-N 0.000 description 2
- RHGLPWUVIKZTEL-UHFFFAOYSA-N 3-(3-methoxy-4-propoxyphenyl)propanoic acid Chemical compound CCCOC1=CC=C(CCC(O)=O)C=C1OC RHGLPWUVIKZTEL-UHFFFAOYSA-N 0.000 description 2
- UHIZYQVRKSWIFO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[3-[3-[(3-phenylphenyl)methyl]triazol-4-yl]phenyl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(C=CC=2)C=2N(N=NC=2)CC=2C=C(C=CC=2)C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 UHIZYQVRKSWIFO-UHFFFAOYSA-N 0.000 description 2
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 2
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 2
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 2
- CONYTTFKIUJZOF-UHFFFAOYSA-N 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoic acid Chemical compound CCCCCC1CC1CC1C(CCCCCCCC(O)=O)C1 CONYTTFKIUJZOF-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LUZOFMGZMUZSSK-UHFFFAOYSA-N Indolactam-V Natural products C1C(CO)NC(=O)C(C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 2
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 2
- DYYZXRCFCVDSKD-UHFFFAOYSA-N N6,N6-dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 DYYZXRCFCVDSKD-UHFFFAOYSA-N 0.000 description 2
- HTUBKQUPEREOGA-UHFFFAOYSA-N PD 168393 Chemical compound BrC1=CC=CC(NC=2C3=CC(NC(=O)C=C)=CC=C3N=CN=2)=C1 HTUBKQUPEREOGA-UHFFFAOYSA-N 0.000 description 2
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 2
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 2
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 2
- 229960005539 bryostatin 1 Drugs 0.000 description 2
- LIPGUSBNMQRYNL-IZBIBDMISA-N bryostatin 2 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 LIPGUSBNMQRYNL-IZBIBDMISA-N 0.000 description 2
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229950002205 dacomitinib Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 2
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- BZHDPIVTQKXAQQ-UHFFFAOYSA-N n-(3-bromophenyl)-1h-imidazo[4,5-g]quinazolin-8-amine Chemical compound BrC1=CC=CC(NC=2C3=CC=4NC=NC=4C=C3N=CN=2)=C1 BZHDPIVTQKXAQQ-UHFFFAOYSA-N 0.000 description 2
- ZNNWCQCQUKAMGL-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[4-(diethylaminomethyl)piperidin-1-yl]pyrimido[5,4-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C1CC(CN(CC)CC)CCN1C1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 ZNNWCQCQUKAMGL-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- DLPSDPPZXRJQOY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]but-2-ynamide Chemical compound N1=CN=C2C=NC(NC(=O)C#CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 DLPSDPPZXRJQOY-UHFFFAOYSA-N 0.000 description 2
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 2
- XGPRSRGBAHBMAF-NQWCLMGHSA-N phorbol-12,13-dihexanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCCCC)C1(C)C XGPRSRGBAHBMAF-NQWCLMGHSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- IARFVGONSLXBCF-UHFFFAOYSA-N propyl 3-(3-methoxy-4-propoxyphenyl)propanoate Chemical compound CCCOC(=O)CCC1=CC=C(OCCC)C(OC)=C1 IARFVGONSLXBCF-UHFFFAOYSA-N 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 2
- 229940073454 resiniferatoxin Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- NSXLMTYRMFVYNT-UHFFFAOYSA-N (1-hydroxy-3-octadecanoyloxypropan-2-yl) icosa-5,8,11,14-tetraenoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC NSXLMTYRMFVYNT-UHFFFAOYSA-N 0.000 description 1
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- ZQBULZYTDGUSSK-KRWDZBQOSA-N 1,2-dioctanoyl-sn-glycerol Chemical compound CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC ZQBULZYTDGUSSK-KRWDZBQOSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PWTCCMJTPHCGMS-YRBAHSOBSA-N 1-Oleoyl-2-acetyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(C)=O PWTCCMJTPHCGMS-YRBAHSOBSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- CBQLIQOITRGNBE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-(6-iodo-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NC1=NC2=CC=C(I)C=C2S1 CBQLIQOITRGNBE-UHFFFAOYSA-N 0.000 description 1
- CJBZBOQPGGQIOM-UHFFFAOYSA-N 2-(4-hydroxy-3-methoxyphenyl)propanoic acid Chemical compound COC1=CC(C(C)C(O)=O)=CC=C1O CJBZBOQPGGQIOM-UHFFFAOYSA-N 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical compound C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- IDQKCIAJGRMMNC-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)butanoic acid Chemical compound COC1=CC=C(CCCC(O)=O)C=C1OC IDQKCIAJGRMMNC-UHFFFAOYSA-N 0.000 description 1
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- ADXSZLCTQCWMTE-UHFFFAOYSA-N 4-n-(3-bromophenyl)quinazoline-4,6,7-triamine Chemical compound C=12C=C(N)C(N)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 ADXSZLCTQCWMTE-UHFFFAOYSA-N 0.000 description 1
- LULATDWLDJOKCX-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C(=CC=C(O)C=2)O)=C1 LULATDWLDJOKCX-UHFFFAOYSA-N 0.000 description 1
- KFLWBZPSJQPRDD-ONEGZZNKSA-N 5-[(e)-2-nitroethenyl]-1,3-benzodioxole Chemical compound [O-][N+](=O)\C=C\C1=CC=C2OCOC2=C1 KFLWBZPSJQPRDD-ONEGZZNKSA-N 0.000 description 1
- MJMJERJFCHYXEM-UHFFFAOYSA-N 5-chloro-N-heptyl-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NCCCCCCC)=CC=CC2=C1Cl MJMJERJFCHYXEM-UHFFFAOYSA-N 0.000 description 1
- IFPPYSWJNWHOLQ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2Cl)Cl)C(=O)N2C)C2=N1 IFPPYSWJNWHOLQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000837181 Andina Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ROPGZJBDGZUMOY-UHFFFAOYSA-N COc(ccc(CCCCC(Nc([s]c1c2)nc1ccc2[N+]([O-])=O)=O)c1)c1OC Chemical compound COc(ccc(CCCCC(Nc([s]c1c2)nc1ccc2[N+]([O-])=O)=O)c1)c1OC ROPGZJBDGZUMOY-UHFFFAOYSA-N 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- RXSVYGIGWRDVQC-UHFFFAOYSA-N N-[6-[[(cyclohexylideneamino)oxy-oxomethyl]amino]hexyl]carbamic acid (cyclohexylideneamino) ester Chemical compound C1CCCCC1=NOC(=O)NCCCCCCNC(=O)ON=C1CCCCC1 RXSVYGIGWRDVQC-UHFFFAOYSA-N 0.000 description 1
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100025482 Voltage-dependent T-type calcium channel subunit alpha-1H Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940085398 ascorbic acid 50 mg Drugs 0.000 description 1
- CRYMJHJFLJAFNU-UHFFFAOYSA-N benzo[a]pyrene-7,8-dione Chemical compound C1=C2C=C(C(C(=O)C=C3)=O)C3=C(C=C3)C2=C2C3=CC=CC2=C1 CRYMJHJFLJAFNU-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MAEVSPLUELJOMM-UHFFFAOYSA-N caffeic acid methyl ester Natural products COC(=O)C=CC1=CC=C(O)C=C1O MAEVSPLUELJOMM-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-M lipoxin A4(1-) Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O IXAQOQZEOGMIQS-SSQFXEBMSA-M 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BQCNSTFWSKOWMA-UHFFFAOYSA-N methyl grevillate Natural products COC(=O)C=CC1=CC(O)=CC=C1O BQCNSTFWSKOWMA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- WPOXAFXHRJYEIC-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CN=2)=C1 WPOXAFXHRJYEIC-UHFFFAOYSA-N 0.000 description 1
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/98—Xeno-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Definitions
- the present invention relates to a method for inducing myocardial differentiation of pluripotent stem cells using a low molecular weight compound and a kit for promoting myocardial differentiation.
- Heart disease is the world's leading cause of death, and heart transplantation is the only treatment for patients with severe heart failure, but there is a problem of insufficient donors.
- transplantation of cardiomyocytes derived from pluripotent stem cells such as ES cells and iPS cells is regarded as promising, and immediate realization is desired.
- ES cells and iPS cells transplantation of cardiomyocytes derived from pluripotent stem cells
- cytokines and proteins contained in the current differentiation-inducing medium are problematic. All of these proteins are produced by animal cells, bacteria, yeast, and the like, and thus there is a risk of infection (viruses, mycoplasma, prions, etc.) from the original cells. Since myocardial differentiation induction is a step before the transplantation, the risk of infection here should be reduced as much as possible.
- An object of the present invention is to provide a myocardial differentiation induction method using a low molecular weight compound.
- the present invention provides the following. 1. A method for inducing myocardial differentiation of pluripotent stem cells, comprising the following steps: (1) culturing pluripotent stem cells in a medium containing a WNT signal activator and a PKC activator; and (2) A step of culturing the cells obtained in step (1) in a medium containing a WNT signal inhibitor, a Src inhibitor, and an EGF receptor inhibitor. 2. 2.
- the Wnt signal inhibitor is a compound of the following formula (I) or a salt thereof:
- R 12 and R 13 are each independently a straight chain of 1 to 5 carbon atoms substituted with a hydrogen atom, an oxygen atom, or an unsubstituted or halogen atom, or Where two adjacent R 1 —R 5 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; and a 1 to 5 carbon atom substituted with a group —C (O) A.
- a straight-chain or branched alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a straight-chain or branched alkyl group having 1 to 5 carbon atoms, and the ring is a nitrogen atom, an oxygen atom, And 1 or 2 atoms independently selected from a sulfur atom); a straight-chain or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom), Although in two adjacent of R 6 -R 9 together O-CH 2 -O- or -O- (CH 2) may form a 2 -O-, R 10 to R 11 are each independently
- R 1 , R 4 , R 5 , R 6 , R 9 , R 10 and R 11 are hydrogen atoms;
- R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group,
- R 7 is a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O)
- A Is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is independently selected from a nitrogen atom, an oxygen atom and a sulfur atom A straight or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or
- R 1 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 and R 11 are hydrogen atoms;
- R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group,
- R 7 is a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O)
- A Is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is independently selected from a nitrogen atom, an oxygen atom and a sulfur atom A straight or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen
- Wnt signal inhibitor is a compound selected from the following or a salt thereof: KY02111 KY010104 T61164 KY02114 KY01045 KY01040 KY02109 KY010104 KY01043 KY01046 PB2852 N11474 PB2572 PB2570 KY02104 SO087 SO102 SO096 SO094 SO3031 (KY01-I) SO2031 (KY02-I) SO3042 (KY03-I) and, SO2077 . 8). 8.
- the medium of step (2) contains two or more WNT signal inhibitors, and one of the two or more WNT signal inhibitors is the compound of formula (I) or a salt thereof according to any one of 2 to 9 above. 10. The method according to any one of 1 to 9, wherein the other WNT signal inhibitor is one or more compounds selected from IWP2, XAV939, and IWR1. 11.
- the 11.2 or more WNT signal inhibitors are the compound of formula (I) or a salt thereof and XAV939 as described in any of 2 to 9 above. 12 12.
- the Src inhibitor is A419259 or SU6656. 17.
- the WNT signal activator is CHIR99021
- the PKC activator is PMA
- the WNT signal inhibitor is a compound selected from KY02111, SO3031 (KY01-I), SO2031 (KY02-I), and SO3042 (KY03-I) and XAV939,
- the WNT signal inhibitor is SO3042 (KY03-I) and XAV939. 22.
- 23. The method according to any one of 1 to 22, wherein the cells are cultured by suspension culture in the steps (1) and (2). 24.
- 24. The method according to any one of 1 to 23, wherein step (1) is from 1 to 3 days and step (2) is from 2 to 13 days. 25.
- the pluripotent stem cell is a monkey or human pluripotent stem cell. 26. 26.
- the pluripotent stem cell is a monkey or human ES cell or iPS cell. 27. 27. The method according to any one of 1 to 26 above, which is a method for producing cardiomyocytes. 28. 28. A cardiomyocyte obtained by the method according to any one of 1 to 27 above. 29. A kit for promoting myocardial differentiation comprising a WNT signal activator, a PKC activator, a WNT signal inhibitor, a Src inhibitor, and an EGF receptor inhibitor. 30.
- the WNT signal activator is CHIR99021
- the PKC activator is PMA
- * (P ⁇ 0.05, ttest), ** (P ⁇ 0.01, ttest), all n 3.
- a protocol for induction of protein-free myocardial differentiation (PFCD) using six kinds of compounds is shown.
- * (P ⁇ 0.05, ttest), all n 4.
- APD90 action potential duration) of PFCD cardiomyocytes under adherent or suspension culture conditions.
- INa voltage-dependent Na channel current of PFCD cardiomyocytes under adherent or suspension culture conditions. * (P ⁇ 0.05, ttest).
- ICa voltage-dependent Ca channel current of PFCD cardiomyocytes under adherent or suspension culture conditions.
- IKr HERG channel current
- IKs KCQN1 channel current
- APD increase increase rate of APD90
- C293B Chromanol293B. * (P ⁇ 0.05, ttest).
- the cardiomyocyte ratio (a) of cells obtained from the human iPS cell line (IMR90-1, 253G1) subcultured under feeder-free and xeno-free conditions by the floating-condition PFCD induction method and a graph (b) summarizing them. Dot data stained with cTnT antibody and analyzed by flow cytometry. Negative controls are differentiated cells stained without primary antibody. N 3 respectively. Photograph of cardiomyocytes 14 days after induction of PFCD under floating condition (a) or adhesion condition (b) from MEF feeder cultured human iPS cell line (IMR90-1), and feeder free xenofree cultured human iPS cell line in FIG. A photograph (c) of cardiomyocytes 14 days after PFCD induction under floating conditions from (253G1).
- the term “pluripotent stem cell” means pluripotency capable of differentiating into all cells constituting an adult and self-replication capable of maintaining the pluripotency even after cell division. It means a cell having the ability.
- the “pluripotent stem cell” includes embryonic stem cells (ES cells), embryonic germ cells (EG cells), and induced pluripotent stem cells (iPS cells).
- the species of “pluripotent stem cells” is not particularly limited, but is preferably a mammal, more preferably a rodent or primate, and even more preferably a primate.
- the present invention is suitable for monkey or human pluripotent stem cells, particularly monkey or human ES cells and iPS cells.
- ES cells are pluripotent stem cells derived from early embryos, and can be established from the inner cell mass of blastocysts or epiblasts of early embryos after implantation.
- ES cells include humans (Thomson J. A. et al., Science 282: 1145-1147 (1998), Biochem Biophys Res Commun. 345 (3), 926-32 (2006); primates such as rhesus monkeys and marmosets (Thomson J. A. et al., Proc. Natl. Acad. Sci. USA 92: 7844-7848 (1995); Thomson J. A. et al., Biol. Reprod.
- CMK6.4, KhES-1, KhES-3, KhES-4, KhES-5, H1, H9, etc. can be used as ES cells.
- EG cells are pluripotent stem cells derived from primordial germ cells.
- human EG cells (Shamblott, et al., Proc. Natl. Acad. Sci USA 95: 13726-13731 (1998)) (this book by reference) Included in the specification).
- iPS cell means a pluripotent stem cell derived from a cell other than a pluripotent stem cell such as a somatic cell or a tissue stem cell.
- Methods for producing iPS cells include, for example, WO2007 / 069666, WO2009 / 006930, WO2009 / 006997, WO2009 / 007852, WO2008 / 118820, Cell Stem Cell 3 (5): 568-574 (2008), Cell Stem Cell 4 (5 ): 381-384 (2009), Nature 454: 646-650 (2008), Cell 136 (3): 411-419 (2009), Nature Biotechnology 26: 1269-1275 (2008), Cell Stem Cell 3: 475- 479 (2008), Nature Cell Biology 11: 197-203 (2009), Cell 133 (2): 250-264 (2008), Cell 131 (5): 861-72 (2007), Science 318 (5858): 1917 -20 (2007), which are incorporated herein by reference.
- iPS cells cells produced by any method are included in the “iPS cells” of the present invention as long as they are artificially induced pluripotent stem cells.
- iPS cells IMR90-1, IMR90-4, 201B7, 253G1, and the like can be used.
- the “Wnt signal activator” in the present invention means a substance that activates the Wnt signal pathway.
- Wnt signal activators include GIO3 ⁇ inhibitors such as BIO and CHIR99021 and TWS119.
- the Wnt signal activator is CHIR99021 or BIO, preferably CHIR99021.
- two or more Wnt signal activators may be used in combination, for example, both CHIR99021 and BIO may be used.
- the “Wnt signal inhibitor” in the present invention means a substance that inhibits the Wnt signal pathway.
- the Wnt signal inhibitor include compounds of the formula (I) described in International Publication No. 2012/026491 or a salt thereof, compounds such as IWP2, IWP4, XAV939, and IWR1.
- two or more Wnt signal inhibitors may be used in combination.
- one of the two or more Wnt signal inhibitors is a compound of formula (I) or a salt thereof as described in WO 2012/026491
- the other Wnt signal inhibitor is IWP2, XAV939, and One or more compounds selected from IWR1, preferably XAV939.
- Any of the two or more Wnt signal inhibitors may be a compound of the formula (I) described in International Publication No. 2012/026491 or a salt thereof.
- R 1 to R 5 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a straight or branched alkoxy group having 1 to 5 carbon atoms; a straight chain having 1 to 5 carbon atoms that is unsubstituted or substituted with a halogen atom.
- R 12 and R 13 are each independently a straight chain of 1 to 5 carbon atoms substituted with a hydrogen atom, an oxygen atom, or an unsubstituted or halogen atom, or Where two adjacent R 1 —R 5 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; and a 1 to 5 carbon atom substituted with a group —C (O) A.
- a straight-chain or branched alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a straight-chain or branched alkyl group having 1 to 5 carbon atoms, and the ring is a nitrogen atom, an oxygen atom, And 1 or 2 atoms independently selected from a sulfur atom); a straight-chain or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom), Although in two adjacent of R 6 -R 9 together O-CH 2 -O- or -O- (CH 2) may form a 2 -O-, R 10 to R 11 are each independently
- linear or branched alkoxy group having 1 to 5 carbon atoms examples include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, and pentyloxy group. Can be mentioned.
- Examples of the linear or branched alkyl group having 1 to 5 carbon atoms include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, and a pentyl group. .
- linear or branched acyl group having 1 to 5 carbon atoms examples include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, and isovaleryl group.
- each of R 1 to R 5 independently represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 carbon atom.
- R 1 to R 5 independently represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 carbon atom.
- R 2 and R 3 are preferably straight-chain or branched alkoxy groups having 1 to 5 carbon atoms, or together, —O—CH 2 —O— or —O— (CH 2 ) 2 —. O- is formed. More preferably, R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group, and even more preferably a methoxy group.
- R 1 , R 4 and R 5 are preferably hydrogen atoms.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms; Or a group —NR 12 R 13 (wherein R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms) Where two adjacent R 6 —R 9 together are —O—CH 2 —O— or —O— (CH 2 ) 2 —O - May be formed.
- R 6 and R 9 are preferably each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms.
- 5 is a linear or branched alkyl group, and more preferably a hydrogen atom.
- R 7 represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched group having 1 to 5 carbon atoms substituted with a group —C (O) A.
- An alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted by a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is formed from a nitrogen atom, an oxygen atom, and a sulfur atom; 1 or 2 atoms independently selected); a linear or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 are each independently a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom, and R 8 is Hydrogen atom; halogen atom; hydroxyl group; carbon number 1 5 straight or branched alkoxy group; or unsubstituted or a straight-chain or branched alkyl group of
- R 7 is a linear alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O) A, and the group —C (O) A is bonded to the terminal carbon atom of the alkoxy group. is doing.
- A contains at least one nitrogen atom, and such A includes pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolyl, imidazolyl, which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms.
- Pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl groups are examples of the group.
- A is a piperidinyl group, piperazinyl group, or morpholinyl group that is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms.
- A is a piperidin-1-yl group, piperazin-1-yl group, or morpholin-4-yl group which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms. is there.
- R 10 and R 11 are preferably a hydrogen atom.
- n is an integer from 0 to 4, 1 to 4, or 1 to 3, or 2 or 3.
- X is an oxygen atom; a sulfur atom; a group —NR 15 (wherein R 15 is a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, a linear or branched acyl group having 1 to 5 carbon atoms). Is). X is preferably a sulfur atom.
- the compound of formula (I) is: R 1 , R 4 , R 5 , R 6 , R 9 , R 10 and R 11 are hydrogen atoms; R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group, R 7 is a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O) A (A Is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is independently selected from a nitrogen atom, an oxygen atom and a sulfur atom A straight or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with
- the compound of formula (I) is: R 1 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 and R 11 are hydrogen atoms; R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group, R 7 is a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O) A (A Is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is independently selected from a nitrogen atom, an oxygen atom and a sulfur atom A straight or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted
- the compound of formula (I) is: R 1 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 and R 11 are hydrogen atoms; R 7 is a halogen atom; R 2 and R 3 are each independently a methoxy group, an ethoxy group, or a propoxy group, X is a sulfur atom, and n is an integer of 0 to 4, preferably 1 to 4.
- the compound of formula (I) is: R 1 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 and R 11 are hydrogen atoms; R 7 is a halogen atom; R 2 and R 3 are methoxy groups, X is a sulfur atom, and n is an integer of 0 to 4, preferably 1 to 4.
- the compound of formula (I) is selected from: KY02111 KY010104 T61164 KY02114 KY01045 KY01040 KY02109 KY010104 KY01043 KY01046 PB2852 N11474 PB2572 PB2570 KY02104 SO087 SO102 SO096 SO094 SO3031 (KY01-I) SO2031 (KY02-I) SO3042 (KY03-I) SO2077 .
- the compound of formula (I) is preferably KY02111, SO3031 (KY01-I), SO2031 (KY02-I), or SO3042 (KY03-I), more preferably KY02111 or SO3042 (KY03-I), Even more preferably, it is SO3042 (KY03-I).
- Compounds of formula (I) can be prepared by known methods (J. Med. Chem., 1965, 8 (5), pp 734-735) (incorporated herein by reference) or in WO 2012/026491. Can be synthesized according to the method described in No. Pamphlet (included herein by reference). Alternatively, they can be obtained from UkrOrgSynthesis (PB2852, PB2572, PB2570), ENAMINE (T61164), and the like.
- PKC activator means a substance that activates protein kinase C (PKC) or a signal transduction pathway downstream thereof.
- PKC activators include phorbol 12-myristate 13-acetate (PMA), prostratin, bryostatin 1 (Bryostatin 1), bryostatin 2 (Bryostatin 2), FR236924, ( -)-Indolactam V ((-)-Indolactam V), PEP005, Phorbol 12,13-dibutyrate, SC-9, SC-10, 1-oleoyl-2-acetyl-sn 1-Oleoyl-2-acetyl-sn-glycerol, 1-O-hexadecyl-2-O-arachidonyl-sn-glycerol, 1 , 2-Dioctanoyl-sn-glycerol, PIP2, Resiniferatoxin, Phorbol 12,13-dihexanoate (Phor
- the PKC activator is a phorbol ester-based PKC activator, PMA, prostratin, PEP005, phorbol 12,13-dibutyrate, resiniferatoxin, phorbol 12,13-dihexanoate, Mezerein, or ingenol 3-angelate.
- two or more PKC activators may be used in combination.
- the PKC activator is PMA or prostratin, more preferably PMA.
- Src inhibitor means a substance that inhibits Src, which is a tyrosine kinase, or a signal transduction pathway downstream thereof.
- Src inhibitors include A419259, SU6656, PP1, 1-naphthyl PP1 (1-Naphthyl1PP1), PP2, indirubin-3 ′-(2,3-dihydroxypropyl) -oxime ether (Indirubin-3 ′-(2, 3-dihydroxypropyl) -oximether), TX-1123, Src Kinase Inhibitor I (CAS 179248-59-0), AZM475271, Bosutinib, Herbimycin A, KB SRC 4, MNS, PD166285, TC- S7003 and the like are exemplified.
- the Src inhibitor is A419259, KB SRC 4, SU6656, or indirubin-3 '-(2,3-dihydroxypropyl) -oxime ether.
- two or more Src inhibitors may be used in combination.
- the Src inhibitor is A419259 or SU6656, more preferably A419259.
- EGF receptor inhibitor (also referred to as EGFR inhibitor) means a substance that inhibits signal transduction from the EGF receptor.
- EGF receptor inhibitors include AG1478, Gefitinib, Afatinib, ARRY334543, AST1306, AZD8931, BIBU1361, BIBX1382, BPQ, BPIQ-I, BPIQ-II, Canertinib5, Canertinib78 CUDC101, Dacomitinib, Vandetanib, EGFR Inhibitor III (N- (4-((3,4-dichloro-6-fluorophenyl) amino) -quinazolin-6-yl) -2-chloroacetamide, CAS 733009-42-2), EGFR / ErbB-2 Inhibitor (4- (4-benzyloxyanilino) -6,7-dimethoxyquinazoline, CAS 179248-61-4), Erlotinib, GW58340,
- the EGF receptor inhibitor is an EGF receptor inhibitor having a quinazoline-based skeleton, such as AG1478, gefitinib, afatinib, ARRY334543, AST1306, AZD8931, BIBU1361, BIBX1382, BPDQ, BPIQ-I, BPIQ-II, Caneltinib CL-387,785, CUDC101, dacomitinib, vandetanib, EGFR Inhibitor III (CAS 733009-42-2), EGFR / ErbB-2 Inhibitor (CAS 179248-61-4), erlotinib, GW58340, GW2974, HDS029, lapatinib, WHI-P154, OSI-420, PD153035, PD168393, PD174265, peritinib, Compound 56, or XL657.
- the EGF receptor inhibitor is AG1478 or gefitinib, more
- the method for inducing cardiomyocytes of pluripotent stem cells of the present invention is performed in vitro.
- the medium used in the method of the present invention may be a medium generally used for myocardial differentiation of pluripotent stem cells (hereinafter also referred to as myocardial differentiation medium), and its composition is not particularly limited.
- the medium used in the method of the present invention may contain a protein component or a peptide component, but preferably does not contain it.
- the medium in the present invention includes, for example, IMDM medium and / or DMEM medium, MEM non-essential amino acid solution, and L-glutamine.
- the medium may contain L-carnitine, ascorbic acid, and / or creatine in addition to IMDM medium and / or DMEM medium, MEM non-essential amino amino acid solution, and L-glutamine.
- the medium may contain an antibiotic such as penicillin-streptomycin as necessary.
- a medium used in the method of the present invention a medium based on IMDM and DMEM used in Examples (IMDM 242 ml, DMDM 242 ml, MEM non-essential amino acid solution ( ⁇ 100) 5 ml, penicillin-streptomycin ( ⁇ 100) 5 ml, 0.2 M L-glutamine 5 ml, 1 M L-carnitine 100 ⁇ l, ascorbic acid 50 mg, 0.5 M creatine 1 ml).
- a myocardial differentiation medium based on a known IMDM medium for example, IMDM medium 200 ml, fetal calf serum 50 ml, MEM non-essential amino acid solution ( ⁇ 100) 2.5 ml, penicillin-streptomycin) ( ⁇ 100) 2.5 ml, 200 mM L-glutamine 2.5 ml, 2-mercaptoethanol 2 ⁇ 1, 5N NaOH 255 ⁇ l), myocardial differentiation medium based on known DMEM medium (for example, DMEM / F12 medium 200 ml, fetal bovine Serum 50 ml, MEM non-essential amino acid solution ( ⁇ 100) 2.5 ml, penicillin-streptomycin ( ⁇ 100) 2.5 ml, 200 mM L-glutamine 2.5 ml, containing 2-mercaptoethanol), or StemPro (registered trademark) -34SFM (GIBCO)
- IMDM medium for example, IMDM medium 200 ml, fetal cal
- a culture method generally suitable for cardiac differentiation of pluripotent stem cells can be used.
- the culture method include an adhesion culture method, a suspension culture method, and a suspension culture method.
- the method of the present invention is performed by a suspension culture method.
- the number of pluripotent stem cells at the start of culture is appropriately determined depending on the culture method, culture vessel, cell type, etc. If seeded at about 1 ⁇ 10 5 cells / ml to 10 ⁇ 10 5 cells / ml. Good.
- the medium may be changed once every 1 to 3 days, for example once every 2 days.
- Step (2) may be started immediately after the end of step (1), or may be started after a certain period from the end of step (1).
- the cells are placed in a medium containing neither a WNT signal activator, a PKC activator, a WNT signal inhibitor, a Src inhibitor, or an EGF receptor inhibitor for 1-2 days.
- the medium may be replaced with a medium containing a WNT signal inhibitor, a Src inhibitor, and an EGF receptor inhibitor, and step (2) may be started.
- the step (1) is performed for 1 to 3 days, and then the step (2) is performed immediately after the completion of the step (1) or after 1 to 2 days after the completion of the step (1). It is carried out for ⁇ 13 days, preferably 3 to 10 days, more preferably 4 to 10 days, even more preferably 4 to 8 days.
- step (1) is performed on days 0 to 1, 0 to 2, or 0 to 3, and immediately after the end of step (1) or 1-2 days after the end of (1), 2-10 days (8 days), 2-9 days (7 days), 2-8 days (6 days), 2-7 days (5 days) ) 2-6 days (4 days), 3-10 days (7 days), 3-9 days (6 days), 3-8 days (5 days), 3-7 days (4 days) )
- Step (2) can be performed on days 4-10 (6 days), days 4-9 (5 days), or days 4-8 (4 days).
- step (1) corresponds to the early stage of myocardial differentiation induction, which is the differentiation induction phase from pluripotent stem cells to mesoderm
- the period of step (1) may be determined based on the expression of mesoderm-related genes. it can. Examples of mesoderm-related genes include T, MIXL1, NODAL, and the like.
- Step (2) corresponds to a later stage of induction of myocardial differentiation in which mesoderm is differentiated into cardiomyocytes, and the period can be determined by confirming differentiation into cardiomyocytes. Differentiation into cardiomyocytes can be confirmed by the number of beating cardiomyocytes, expression of myocardial markers, expression of ion channels, response to electrophysiological stimulation, and the like.
- Myocardial markers include ⁇ MHC, ⁇ MHC, cTnT, ⁇ -actinin, and NKX2.5.
- Examples of the ion channel include HCN4, Nav1.5, Cav1.2, Cav3.2, HERG1b, and KCNQ1.
- the concentration of the Wnt signal activator and the Wnt signal inhibitor can be appropriately changed according to the cells and drugs used.
- BIO or CHIR99021 is used as the Wnt signal activator, it may be used, for example, at a final concentration of 100 nM to 100 ⁇ M, preferably 1 ⁇ M to 10 ⁇ M.
- the final concentration may be 0.5 to 20 ⁇ M, preferably 0.5 to 10 ⁇ M, more preferably 1 to 10 ⁇ M.
- a final concentration of 0.1 to 20 ⁇ M, preferably 0.1 to 10 ⁇ M, more preferably 1 to What is necessary is just to use at 10 micromol.
- the concentration of the PKC activator can be changed as appropriate according to the cells and drugs used.
- the final concentration is 0.01 ⁇ M to 10 ⁇ M, preferably 0.03 to 1 ⁇ M, more preferably 0.1 to 1 ⁇ M.
- the final concentration is 0.1 ⁇ M to 100 ⁇ M, preferably 1 to 10 ⁇ M. And you can use it.
- the concentration of the Src inhibitor can be appropriately changed according to the cells and drugs used.
- the final concentration may be 0.1 ⁇ M to 10 ⁇ M, preferably 0.1 ⁇ M to 3 ⁇ M, more preferably 0.3 to 3 ⁇ M.
- the concentration of the EGF receptor inhibitor can be appropriately changed according to the cells and drugs used.
- the final concentration may be 100 nM to 100 ⁇ M, preferably 1 ⁇ M to 20 ⁇ M, and in the case of PP3, the final concentration may be 1 ⁇ M to 1 mM, preferably 10 ⁇ M to 100 ⁇ M.
- the method of the present invention can be used for the production of cardiomyocytes.
- Obtaining cardiomyocytes can be confirmed by the number of beating cardiomyocytes, expression of myocardial markers, expression of ion channels, response to electrophysiological stimulation, and the like.
- the cardiomyocytes obtained by the method of the present invention can be used for in vitro drug safety tests or as transplanted cardiomyocytes for heart disease and the like.
- the myocardial differentiation kit of the present invention includes a WNT signal activator, a PKC activator, a WNT signal inhibitor, a Src inhibitor, and an EGF receptor inhibitor, and further includes a medium, a culture container, and the like used in the method of the present invention. May be included.
- the WNT signal activator, PKC activator, WNT signal inhibitor, Src inhibitor, and EGF receptor inhibitor used in the kit of the present invention are as described for the myocardial differentiation inducing method of the present invention.
- the kit of the present invention comprises CHIR99021 as a WNT signal activator, PMA as a PKC activator, SO3042 (KY03-I) and XAV939 as WNT signal inhibitors, A419259 as an Src inhibitor, and EGF receptor inhibition.
- AG1478 is included as an agent.
- the present invention also includes a pluripotent stem cell myocardial differentiation promoter containing a PKC activator, use of a PKC activator for the production of a pluripotent stem cell myocardial differentiation promoter, and a medium containing a PKC activator
- a method for inducing cardiac differentiation of pluripotent stem cells comprising culturing pluripotent stem cells therein.
- the PKC activator may be used in the early stage of induction of myocardial differentiation, for example, for 1 to 3 days from the start of culture in myocardial differentiation medium.
- the present invention also relates to a pluripotent stem cell myocardial differentiation promoter containing a Src inhibitor, the use of a Src inhibitor for the production of a pluripotent stem cell myocardial differentiation promoter, and a medium containing a Src inhibitor.
- a method for inducing cardiac differentiation of pluripotent stem cells comprising culturing pluripotent stem cells.
- the Src inhibitor is used at a later stage of induction of myocardial differentiation, for example, 2 to 13 days, preferably 3 to 10 days, more preferably 4 to 10 days from the second, third, or fourth day of culture in myocardial differentiation medium. More preferably, it may be used for 4 to 8 days.
- the pluripotent stem cells and medium described above can be used.
- the addition condition of a compound (a compound that promotes myocardial differentiation in addition to KY02111) in which the amount of GFP fluorescence increases three times or more than the condition of KY02111 alone is shown in gray.
- the PKC activator Prostratin, the Src inhibitor A419259, and the EGF inhibitor AG1478 each promoted myocardial differentiation under appropriate conditions.
- FIG. 1a shows an outline of chemical screening.
- GFP in addition to KY02111 compound treatment
- Compounds that increase the amount of fluorescence were screened.
- IMDM medium fetal bovine serum
- a screening compound was added in a concentration-dependent manner for the early stage of myocardial differentiation (day 0-3, Early) and late stage of differentiation (day 4-7, Late), and the amount of GFP fluorescence was increased on day 9 of myocardial differentiation culture. Analyzed with Metamorph imaging system.
- Prostratin ⁇ ⁇ (Fig. 1b) and PMA (Fig. 1c), which are PKC activators, promoted myocardial differentiation in a concentration-dependent manner in the early stage of myocardial differentiation.
- Prostratin (3-10uM) and PMA (0.03-0.3 uM) promoted myocardial differentiation either alone or in combination with KY02111 (10uM, late differentiation) (KY + Prost, KY + PMA) (3-8 times).
- the EGF inhibitors AG1478 and gefitinib promoted myocardial differentiation in a concentration-dependent manner during the late stage of myocardial differentiation (FIG. 1d).
- AG1478 (10-30uM) and gefitinib (10-30uM), either alone or in combination with KY02111 (10uM, late differentiation) (KY + AG, KY + Gef) promoted myocardial differentiation (2 ⁇ 3 times).
- A419259 and SU6656 promoted myocardial differentiation in a concentration-dependent manner during the late stage of myocardial differentiation.
- A419259 (1-3uM) and SU6656 (1-3uM) either alone or in combination with KY02111 (10uM, late differentiation) (KY + A419, KY + SU66) promoted myocardial differentiation (2 ⁇ 5 times).
- Myocardial differentiation was induced in a GFP gene-introduced monkey ES cell line (CMK6.4) using 6 types of compounds, CHIR99021, PMA, KY03-I, XAV939, AG1478, and A419259.
- GFP fluorescence when 1 uM CHIR99021 and 0.1 uM PMA are added in early differentiation (day0-2), 3 uM KY03-I, 1 uM XAV939, 10 uM AG1478 and 0.3 uM A419259 are added in late differentiation (day3-7) was analyzed.
- the administration of these 6 kinds of compounds showed a significant effect of promoting myocardial differentiation (approximately 750 times that of DMSO addition) (FIG. 1f).
- FIG. 2a shows a protocol for induction of protein-free myocardial differentiation (PFCD) using six kinds of compounds.
- PFCD protein-free myocardial differentiation
- Wnt signal inhibitor (3uM KY03-I and 1uM XAV939) and EGFR inhibitor (10uM) in late differentiation (day-3-7) AG1478) and Src inhibitor (0.3 uM A419259) were added in PFCD medium under suspension culture conditions or adhesion culture conditions.
- suspension culture conditions the cells were cultured in a low adhesion dish (Wako 641-07391 or Corning YO-01835-24), and in adhesion culture conditions, they were cultured in a normal dish (Falcon 353004). Even under adhesion conditions, the adhesion culture was performed under protein-free conditions without coating the dish. Pulsating myocardial colonies were usually observed from day 7-9. Differentiated cardiomyocytes could be maintained in PFCD medium for 1-2 months under floating / adhesive conditions.
- Table 2 shows the medium components of the PFCD medium and their purchase prices. It is composed of low molecular weight compounds and amino acids that do not contain proteins or peptides and can be synthesized. It can be manufactured for 1,200 yen or less per 500ml, and it is very inexpensive.
- FIG. 2d shows the results of total cell number analysis of cardiomyocytes induced from PFCD under suspension or adhesion culture conditions from the above pluripotent stem cell lines. The number of differentiated cells obtained from 2 ⁇ 10 6 undifferentiated pluripotent stem cells is shown. For most cell lines, more cells were obtained under suspension culture conditions. Flow cytometric analysis and cell count were all performed on day 14.
- FIG. 3a shows PMA added (left photo, all 6 compounds) Added) and without PMA addition (right photo, addition of 5 compounds other than PMA) GFP when PFCD induction (Fig. 2a) was performed under floating conditions from ⁇ MHC promoter-driven GFP gene-introduced monkey ES cell lines A fluorescent photograph is shown. Almost all colonies were GFP positive in the condition with PMA, whereas almost no GFP fluorescence was seen in the condition without PMA.
- PFCD MEF feeder cultured IMR90-1 strain
- FIG. 3d shows the result of total cell number analysis of cardiomyocytes induced by PFCD under the same conditions as FIG. 3c.
- CHIR99021 and PMA were each removed, the number of cells decreased significantly.
- Flow cytometric analysis and cell count were all performed on day 14.
- each of these four compounds decreased the gene expression level of MSGN1, T, and MIXL1, and the expression level thereof was most significantly decreased by the simultaneous addition of the four compounds.
- NODAL no significant change in the expression level was observed with the addition of each of the four compounds, but the expression level was significantly increased by the simultaneous addition of the four compounds.
- Coordinated changes in mesoderm gene expression due to the addition of these four compounds may contribute to efficient PFCD. In general, it is known that the expression of mesoderm-related genes increases during the early stage of myocardial differentiation and decreases during the late stage of differentiation.
- PFCD induction method Expression of myocardial markers and channels in cardiomyocytes derived from human pluripotent stem cells by PFCD induction method.
- the gene expression of PFCD cardiomyocytes was analyzed by quantitative PCR.
- total mRNA was collected from PFCD cardiomyocytes (derived from MEF feeder culture IMR90-1) under floating and adhesion conditions, and myocardial markers and channel genes were expressed by quantitative PCR. Compared.
- the expression level tends to increase, and it can be said that the myocardial maturation has progressed over time.
- the expression levels of ⁇ MHC, ⁇ Actinin, and KCNQ1 were significantly higher in PFCD cardiomyocytes in floating conditions than in adhesion conditions. This suggests that PFCD cardiomyocytes in floating conditions have a higher degree of myocardial maturity than adhesion conditions.
- PFCD cardiomyocytes were analyzed by flow cytometry using antibody staining of MLC2v, a ventricular muscle marker, MLC2a, an atrial muscle marker, HCN4, a pacemaker marker, and cTnT, a marker for all myocardial cells.
- MLC2v a ventricular muscle marker
- MLC2a a ventricular muscle marker
- HCN4 a pacemaker marker
- cTnT a marker for all myocardial cells.
- MLC2v single positive cells about 70% of MLC2v single positive cells and 0.2-0.3% of MLC2a single positive cells were not different between the floating condition and the adhesion condition, but MLC2v / MLC2a The percentage of the double positive cells was about 9% in suspension and 13% in adhesion, which was significantly lower in the suspension conditions (FIGS. 4b and 4c).
- the double positive cells of MLC2v / MLC2a are said to be immature ventricular myocytes, which indicates that there are fewer immature ventricular myocytes in the PFCD cells in the floating condition than in the adhesion condition.
- HCN4 positive cells pacemaker
- cTnT positive cells were about 90% (FIG. 4c). Cells stained without primary antibody served as a negative control. For each sample, 30,000 cells were analyzed with FACSCantoII.
- Electrophysiological analysis of PFCD cardiomyocytes was performed by whole cell patch clamp method.
- PFCD cardiomyocytes derived from MEF feeder cultured IMR90-1
- RP resting membrane potential
- APD90 action potential duration
- Fig. 4d, g there was no significant difference, but with respect to Amplitude (action potential amplitude)
- the floating condition was about 105 mV
- the adhesion condition was about 90 mV
- the RP of mature human adult ventricular myocytes is -80 to -90 mV
- the RP of PFCD cardiomyocytes is about -60 mV, which is a relatively immature shallow RP.
- FIG. This is consistent with the fact that the expression level of Kir2.1, which is important for the formation of, is generally low in PFCD cardiomyocytes (approximately one-tenth that of human mature myocardial tissue).
- RP is shallow, it is immature cardiomyocyte compared to human mature cardiomyocyte, but in terms of both gene expression level and electrophysiological analysis result, floating PFCD cardiomyocyte adheres more It can be said that maturation is progressing more than the condition cardiomyocytes.
- PFCD cardiomyocytes derived from MEF feeder cultured IMR90-1) 30 days after differentiation induction, the floating conditions and the adhesion conditions were compared. As a result, two types of cardiomyocytes were observed: cardiomyocytes with clear ⁇ Actinin staining pattern (patterned ⁇ Actinin, white arrow) and cardiomyocytes without clear pattern (un-patterned ⁇ Actinin, white triangle). It was done. A lot of patterned cells were observed in PFCD cardiomyocytes under floating conditions, whereas PFCD cardiomyocytes under adhesion conditions had few patterned cells and many un-patterned cells.
- the ratio of patterned cells when PFCD cardiomyocytes were stained with ⁇ -Actinin® was compared between the floating conditions and the adhesion conditions (FIG. 5c). About 80% of myocardial cells were patterned cells in the floating condition, whereas only about 50% of the patterned cells were observed in the adhesion condition, indicating a significantly higher value in the floating condition.
- FIGS. 7a and b show photographs of myocardial cells 14 days after induction of PFCD under floating conditions and 14 days after induction of PFCD under adhesion conditions from MEF feeder cultured human iPS cell line (IMR90-1).
- FIG. 7c shows a photograph of cardiomyocytes 14 days after induction of PFCD under floating conditions from the feeder-free xenofree cultured human iPS cell line (253G1) of FIG.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 167 mg of 2- (2- (3,4-dimethoxyphenyl) acetamido) -6-iodobenzothiazole in a yield of 50%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 83 mg of 2- (3- (3,4-dimethoxyphenyl) propanamide) -6-iodobenzothiazole in a yield of 48%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 131 mg of 2- (4- (3,4-dimethoxyphenyl) butanamide) -6-iodobenzothiazole in a yield of 30%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 217 mg of 2- (3- (3-methoxy-4-propoxyphenyl) propanamide) -6-iodobenzothiazole in a yield of 60%.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1.多能性幹細胞の心筋分化誘導法であって、以下の工程を含む方法:
(1)多能性幹細胞をWNTシグナル活性化剤およびPKC活性化剤を含む培地中で培養する工程、および;
(2)工程(1)で得られた細胞をWNTシグナル阻害剤、Src阻害剤、およびEGF受容体阻害剤を含む培地中で培養する工程。
2.Wntシグナル阻害剤が、以下の式(I)の化合物またはその塩である、前記1に記載の方法:
式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]。
3.R1、R4、R5、R6、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である)であり、
R8が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基であり、又は、
R7及びR8が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成しており、
Xが、硫黄原子であり、および
nが、0から4の整数である、前記2に記載の方法。
4.R1、R4、R5、R6、R8、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)であり、
Xが、硫黄原子であり、および
nが、0から4の整数である、前記2に記載の方法。
5.R7が、ハロゲン原子である、前記4に記載の方法。
6.nが、1から4の整数である、前記3~5のいずれかに記載の方法。
7.Wntシグナル阻害剤が、以下から選択される化合物またはその塩である、前記1に記載の方法:
KY02111
SO2077
8.Wntシグナル阻害剤が、KY02111、SO3031(KY01-I)、SO2031(KY02-I)、またはSO3042(KY03-I)である、前記7に記載の方法。
9.Wntシグナル阻害剤が、SO3042(KY03-I)である、前記8に記載の方法。
10.工程(2)の培地が2種以上のWNTシグナル阻害剤を含み、前記2種以上のWNTシグナル阻害剤の1つが前記2~9のいずれかに記載の式(I)の化合物またはその塩であり、他のWNTシグナル阻害剤がIWP2、XAV939、およびIWR1から選択される1種以上の化合物である、前記1~9のいずれかに記載の方法。
11.2種以上のWNTシグナル阻害剤が、前記2~9のいずれかに記載の式(I)の化合物またはその塩およびXAV939である、前記10に記載の方法。
12.WNTシグナル活性化剤が、BIOまたはCHIR99021である、前記1~11のいずれかに記載の方法。
13.WNTシグナル活性化剤が、CHIR99021である、前記1~12のいずれかに記載の方法。
14.PKC活性化剤が、PMAまたはプロストラチンである、前記1~13のいずれかに記載の方法。
15.PKC活性化剤が、PMAである、前記1~14のいずれかに記載の方法。
16.Src阻害剤が、A419259またはSU6656である、前記1~15のいずれかに記載の方法。
17.Src阻害剤が、A419259である、前記1~16のいずれかに記載の方法。
18.EGF受容体阻害剤が、AG1478またはゲフィチニブである、前記1~17のいずれかに記載の方法。
19.EGF受容体阻害剤が、AG1478である、前記1~18のいずれかに記載の方法。
20.WNTシグナル活性化剤がCHIR99021であり、
PKC活性化剤がPMAであり、
WNTシグナル阻害剤が、KY02111、SO3031(KY01-I)、SO2031(KY02-I)、およびSO3042(KY03-I)から選択される化合物並びにXAV939であり、
Src阻害剤がA419259であり、および
EGF受容体阻害剤がAG1478である、前記1~19のいずれかに記載の方法。
21.WNTシグナル阻害剤が、SO3042(KY03-I)およびXAV939である、前記20に記載の方法。
22.工程(1)および(2)における培地が蛋白質成分およびペプチド成分を含まない、前記1~21のいずれかに記載の方法。
23.工程(1)および(2)において細胞を浮遊培養により培養する、前記1~22のいずれかに記載の方法。
24.工程(1)が1~3日間であり、工程(2)が2~13日間である、前記1~23のいずれかに記載の方法。
25.多能性幹細胞がサルまたはヒト多能性幹細胞である、前記1~24のいずれかに記載の方法。
26.多能性幹細胞がサルまたはヒトES細胞またはiPS細胞である、前記25に記載の方法。
27.心筋細胞の製造方法である、前記1~26のいずれかに記載の方法。
28.前記1~27のいずれかに記載の方法により得られた心筋細胞。
29.WNTシグナル活性化剤、PKC活性化剤、WNTシグナル阻害剤、Src阻害剤、およびEGF受容体阻害剤を含む、心筋分化促進用キット。
30.WNTシグナル活性化剤がCHIR99021であり、
PKC活性化剤がPMAであり、
WNTシグナル阻害剤が、
KY02111
SO3042(KY03-I)
Src阻害剤がA419259であり、および
EGF受容体阻害剤がAG1478である、前記29に記載の心筋分化促進用キット。
31.WNTシグナル阻害剤が、SO3042(KY03-I)およびXAV939である、前記30に記載の心筋分化促進用キット。
式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]。
R1、R4、R5、R6、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である)であり、
R8が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基であり、又は、
R7及びR8が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成しており、
Xが、硫黄原子であり、および
nが、0から4、好ましくは1から4の整数である。
R1、R4、R5、R6、R8、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)であり、
Xが、硫黄原子であり、および
nが、0から4、好ましくは1から4の整数である。
R1、R4、R5、R6、R8、R9、R10及びR11が水素原子であり、
R7が、ハロゲン原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
Xが、硫黄原子であり、および
nが、0から4、好ましくは1から4の整数である。
R1、R4、R5、R6、R8、R9、R10及びR11が水素原子であり、
R7が、ハロゲン原子であり、
R2及びR3が、メトキシ基であり、
Xが、硫黄原子であり、および
nが、0から4、好ましくは1から4の整数である。
KY02111
本発明でスクリーニングを行った20種類の化合物とそれらの心筋分化促進効果を表1に示す。それぞれの化合物について、心筋分化の前期(Early)と後期(Late)において濃度依存的(0.3uM, 1uM, 3uM, 10uM)に培養液に添加し、図1aの心筋分化プロトコールに従いGFP蛍光量の解析を行った。すべての条件において分化後期に10uMのKY02111を添加しており、このKY02111のみの条件におけるGFP蛍光量を1とした。KY02111のみの条件よりも3倍以上GFP蛍光量が増えている化合物(KY02111に対し加算的に心筋分化を促進している化合物)の添加条件をグレーで示している。PKC活性剤のプロストラチン(Prostratin)、Src阻害剤のA419259、およびEGF阻害剤のAG1478が、それぞれ適切な条件において心筋分化を促進していた。
図1aにケミカルスクリーニングの概略を示す。αMHCプロモーター駆動GFP遺伝子導入サルES細胞株(Minami et al., Cell Reports 2, 1448-1460, 2012)(引用により本明細書に含まれる)を用いて、KY02111化合物処理に対して加算的にGFP蛍光量が増加する化合物をスクリーニングした。サルES細胞株(カニクイザルCMK6.4株)に、心筋分化マーカーであるαMHC遺伝子のプロモーターの制御下で緑色蛍光蛋白質(GFP)を発現するベクターを導入し、6ウェルプレート(旭硝子/ 5816-006 :Ezview カルチャープレート)に4.0×105細胞/ウェルにて播種し、IMDM培地を基本とした心筋分化培地(IMDM培地(Sigma l3390) 200 ml、ウシ胎児血清(GIBCO 10099-141) 50 ml、MEM non-essential amino acid solution (Sigma M7145) 2.5 ml、ペニシリン-ストレプトマイシン(GIBCO 15140) 2.5 ml、200 mM L-グルタミン 2.5 ml、2-メルカプトエタノール(Sigma M7522) 2u1、5N NaOH 255ulを混合したもの)で9日間培養した。心筋分化前期(day 0-3、Early)と分化後期(day 4-7、Late)に対し、スクリーニング化合物を濃度依存的に添加し、心筋分化培養9日目(day 9)にGFP蛍光量をMetamorph イメージングシステムで解析した。
6種類の化合物を用いた蛋白質フリー心筋分化(PFCD)誘導法プロトコールを図2aに示す。まず、心筋分化前期(day 0-2)において、多能性幹細胞の浮遊コロニー(Minami, I. et al., Cell reports 2, 1448-1460 (2012)および国際公開第2013/111875号パンフレットに記載のとおり調製)(これら文献は引用により本明細書に含まれる)をGSK3β阻害剤(2 uM CHIR99021) とPKC 活性剤 (0.3 uM PMA または 3 uM プロストラチン)を添加したPFCD培地(表2)により、浮遊培養条件下で培養した。次に、1日間(day 2-3)化合物なしのPFCD培地で培養した後、分化後期(day-3-7)にWntシグナル阻害剤(3uM KY03-Iおよび1uM XAV939)とEGFR阻害剤(10uM AG1478)、Src阻害剤(0.3 uM A419259)を添加したPFCD培地中で、浮遊培養条件下あるいは接着培養条件下で培養した。浮遊培養条件では低接着ディッシュ(和光641-07391またはコーニングYO-01835-24)で、接着培養条件では通常のディッシュ(ファルコン 353004)上で培養した。接着条件においても、ディッシュをコーティングすることなしに、蛋白質フリーの条件下で接着培養した。拍動心筋コロニーは通常day7~9から観察された。分化した心筋細胞はPFCD培地中、浮遊/接着条件下で1~2か月間維持できた。
図3aは、PMA添加あり(左写真、6化合物すべて添加)とPMA添加なし(右写真、PMA以外の5化合物添加)の条件下において、αMHC プロモーター駆動GFP遺伝子導入サルES細胞株から、浮遊条件下でPFCD誘導(図2a)を行った際のGFP蛍光写真を示す。PMAありの条件ではほとんどすべてのコロニーがGFP陽性であるのに対し、PMAなしの条件ではGFP蛍光がほとんど見られなかった。
定量的PCR法により、PFCD心筋細胞の遺伝子発現を解析した。誘導後7、14、30、60日目において、浮遊条件と接着条件のPFCD心筋細胞(MEFフィーダー培養IMR90-1由来)からトータルmRNAを回収し、定量的PCR法で心筋マーカーとチャネル遺伝子の発現を比較した。心筋マーカー (αMHC, βMHC, cTnT, αActinin, NKX2.5)と 心筋チャネル (KCNQ1, HERG1b, Nav1.5, Cav1.2, Kir2.1)について、すべてのサンプルで遺伝子発現が見られた(ヒト成人心臓由来mRNAにおける各心筋関連遺伝子の発現レベルを1とした)(図4a)。ヒト心筋成熟マーカーとして知られるβMHC や心筋静止膜電位の形成に重要であるKir2.1がヒト成人心臓の発現レベルに比べて1/10程度と低く、このPFCD心筋細胞は実際の成人心臓組織に比べてまだ十分に成熟していないと考えられるが、培養日数と共に発現量が増加する傾向が見られおり、経時的には心筋成熟が進んでいると言える。また、βMHC、αActinin、およびKCNQ1について、接着条件よりも浮遊条件のPFCD心筋細胞の方が、発現量が有意に高かった。このことは、浮遊条件のPFCD心筋細胞の方が接着条件よりも心筋成熟度が進んでいることを示唆している。
心筋サルコメアのZ盤マーカーであるαActininと、心筋細胞の転写因子マーカーであるNKX2.5について免疫染色を行った(図5a、b)。細胞核はDAPIにより染色した。分化誘導後30日目のPFCD心筋細胞(MEFフィーダー培養IMR90-1由来)について、浮遊条件と接着条件の比較を行った。その結果、αActinin の明瞭な縞模様状の染色パターンが見られる(patterned αActinin、白矢印)心筋細胞と、明瞭なパターンが見られない(un-patterned αActinin、白三角)心筋細胞の2種類が観察された。浮遊条件のPFCD心筋細胞にはpatterned細胞が多く観察されたのに対し、接着条件のPFCD心筋細胞にはpatterned細胞が少なく、un-patterned細胞が多く観察された。
フィーダーフリー(ラミニンフラグメント接着法、Miyazaki, T. et al. Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun 3, 1236 (2012) (引用により本明細書に含まれる))、かつゼノフリー(Essential8培地、Chen, G. et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8, 424-429 (2011) (引用により本明細書に含まれる))の条件で継代培養したヒトiPS細胞株(IMR90-1、253G1)から浮遊条件PFCD誘導法により得られた細胞の心筋細胞率を調べた(図6a、b)。心筋マーカーであるcTnT抗体で染色し、フローサイトメトリーにより解析した。それぞれのサンプルについて30,000個の細胞をFACSCantoIIで解析した。MEFフィーダー細胞を用いず、動物由来成分を含まないゼノフリーのEssential8培地で培養した未分化iPS細胞株からでも、PFCD誘導が約85%の心筋細胞率で可能であった。上記のフィーダーフリー・ゼノフリーの多能性幹細胞培養法は蛋白質フリーではない(5種類の蛋白質を使用している、上記論文Chen,G. et al参照)ものの、現時点で最も臨床に適した未分化多能性幹細胞の培養法であり、この条件のiPS細胞からPFCD誘導によって得られたこれらの心筋細胞は、現時点で最も臨床グレードの条件を満たしている。
SO3031(KY01-I)
1H NMR (DMSO-d6): δ 12.61 (s, 1H), 8.37 (s, 1H), 7.73-7.69 (m ,1H), 7.54 (d, J = 8.0 Hz, 1H), 6.97-6.84 (m, 3H), 3.75-3.72 (m, 8H).
MS (ESI) Found; 455 [M+H]+
1H NMR (DMSO-d6): δ 12.42 (s, 1H), 8.37 (s, 1H), 7.72-7.69 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.85-6.83 (m, 2H), 6.75-6.72 (m, 1H), 3.71 (s, 3H), 3.69 (s, 3H), 2.90-2.76 (m, 4H).
MS (ESI) Found; 469 [M+H]+
1H NMR (DMSO-d6): δ 12.37 (s, 1H), 8.37 (s, 1H), 7.72-7.69 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.86-6.79 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 2.58-2.48 (m, 4H), 1.96-1.86 (m, 2H).
MS (ESI) Found; 483 [M+H]+
1H NMR (DMSO-d6): δ 12.42 (s, 1H), 8.38-8.37 (m, 1H), 7.72-7.69 (m, 1H), 7.54-7.51 (m, 1H), 6.85-6.82 (m, 2H), 6.72 (d, J = 8.0 Hz, 1H), 3.86-3.82 (m, 2H), 3.72 (s, 3H), 2.87-2.78 (m, 4H), 1.72-1.65 (m, 2H), 094 (t, J = 7.3 Hz, 3H).
MS (ESI) Found; 497 [M+H]+
Claims (31)
- 多能性幹細胞の心筋分化誘導法であって、以下の工程を含む方法:
(1)多能性幹細胞をWNTシグナル活性化剤およびPKC活性化剤を含む培地中で培養する工程、および;
(2)工程(1)で得られた細胞をWNTシグナル阻害剤、Src阻害剤、およびEGF受容体阻害剤を含む培地中で培養する工程。 - Wntシグナル阻害剤が、以下の式(I)の化合物またはその塩である、請求項1に記載の方法:
式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]。 - R1、R4、R5、R6、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である)であり、
R8が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基であり、又は、
R7及びR8が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成しており、
Xが、硫黄原子であり、および
nが、0から4の整数である、請求項2に記載の方法。 - R1、R4、R5、R6、R8、R9、R10及びR11が水素原子であり、
R2及びR3が、各々独立して、メトキシ基、エトキシ基、又はプロポキシ基であり、
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)であり、
Xが、硫黄原子であり、および
nが、0から4の整数である、請求項2に記載の方法。 - R7が、ハロゲン原子である、請求項4に記載の方法。
- nが、1から4の整数である、請求項3~5のいずれかに記載の方法。
- Wntシグナル阻害剤が、KY02111、SO3031(KY01-I)、SO2031(KY02-I)、またはSO3042(KY03-I)である、請求項7に記載の方法。
- Wntシグナル阻害剤が、SO3042(KY03-I)である、請求項8に記載の方法。
- 工程(2)の培地が2種以上のWNTシグナル阻害剤を含み、前記2種以上のWNTシグナル阻害剤の1つが請求項2~9のいずれかに記載の式(I)の化合物またはその塩であり、他のWNTシグナル阻害剤がIWP2、XAV939、およびIWR1から選択される1種以上の化合物である、請求項1~9のいずれかに記載の方法。
- 2種以上のWNTシグナル阻害剤が、請求項2~9のいずれかに記載の式(I)の化合物またはその塩およびXAV939である、請求項10に記載の方法。
- WNTシグナル活性化剤が、BIOまたはCHIR99021である、請求項1~11のいずれかに記載の方法。
- WNTシグナル活性化剤が、CHIR99021である、請求項1~12のいずれかに記載の方法。
- PKC活性化剤が、PMAまたはプロストラチンである、請求項1~13のいずれかに記載の方法。
- PKC活性化剤が、PMAである、請求項1~14のいずれかに記載の方法。
- Src阻害剤が、A419259またはSU6656である、請求項1~15のいずれかに記載の方法。
- Src阻害剤が、A419259である、請求項1~16のいずれかに記載の方法。
- EGF受容体阻害剤が、AG1478またはゲフィチニブである、請求項1~17のいずれかに記載の方法。
- EGF受容体阻害剤が、AG1478である、請求項1~18のいずれかに記載の方法。
- WNTシグナル活性化剤がCHIR99021であり、
PKC活性化剤がPMAであり、
WNTシグナル阻害剤が、KY02111、SO3031(KY01-I)、SO2031(KY02-I)、およびSO3042(KY03-I)から選択される化合物並びにXAV939であり、
Src阻害剤がA419259であり、および
EGF受容体阻害剤がAG1478である、請求項1~19のいずれかに記載の方法。 - WNTシグナル阻害剤が、SO3042(KY03-I)およびXAV939である、請求項20に記載の方法。
- 工程(1)および(2)における培地が蛋白質成分およびペプチド成分を含まない、請求項1~21のいずれかに記載の方法。
- 工程(1)および(2)において細胞を浮遊培養により培養する、請求項1~22のいずれかに記載の方法。
- 工程(1)が1~3日間であり、工程(2)が2~13日間である、請求項1~23のいずれかに記載の方法。
- 多能性幹細胞がサルまたはヒト多能性幹細胞である、請求項1~24のいずれかに記載の方法。
- 多能性幹細胞がサルまたはヒトES細胞またはiPS細胞である、請求項25に記載の方法。
- 心筋細胞の製造方法である、請求項1~26のいずれかに記載の方法。
- 請求項1~27のいずれかに記載の方法により得られた心筋細胞。
- WNTシグナル活性化剤、PKC活性化剤、WNTシグナル阻害剤、Src阻害剤、およびEGF受容体阻害剤を含む、心筋分化促進用キット。
- WNTシグナル阻害剤が、SO3042(KY03-I)およびXAV939である、請求項30に記載の心筋分化促進用キット。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016523588A JP6651218B2 (ja) | 2014-05-30 | 2015-05-29 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
US15/314,409 US10233426B2 (en) | 2014-05-30 | 2015-05-29 | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
EP15799980.6A EP3150705B1 (en) | 2014-05-30 | 2015-05-29 | Method for inducing myocardial differentiation of pluripotent stem cells using low-molecular compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014113325 | 2014-05-30 | ||
JP2014-113325 | 2014-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015182765A1 true WO2015182765A1 (ja) | 2015-12-03 |
Family
ID=54699083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/065643 WO2015182765A1 (ja) | 2014-05-30 | 2015-05-29 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10233426B2 (ja) |
EP (1) | EP3150705B1 (ja) |
JP (1) | JP6651218B2 (ja) |
WO (1) | WO2015182765A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017159862A1 (ja) | 2016-03-18 | 2017-09-21 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
WO2018124210A1 (ja) * | 2016-12-28 | 2018-07-05 | 国立大学法人京都大学 | 環状心筋細胞塊 |
WO2019078278A1 (ja) | 2017-10-18 | 2019-04-25 | 国立大学法人京都大学 | 心筋細胞に分化させるための多能性幹細胞の製造方法 |
WO2019131806A1 (ja) | 2017-12-26 | 2019-07-04 | 株式会社マイオリッジ | 心筋細胞の薬剤応答性試験方法 |
WO2019189553A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 複素環化合物 |
WO2020009188A1 (ja) | 2018-07-06 | 2020-01-09 | 株式会社マイオリッジ | 細胞シートの製造方法、心筋細胞シート、および心筋細胞シート製造用キット |
JP2021126066A (ja) * | 2020-02-12 | 2021-09-02 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2021251394A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社マイオリッジ | 向上した心筋細胞純度を有する心筋細胞集団の製造方法、心筋細胞の純化方法、心筋細胞集団、および移植材料 |
WO2022014622A1 (ja) * | 2020-07-14 | 2022-01-20 | 株式会社カネカ | 心筋細胞塊の製造方法 |
WO2022138101A1 (ja) | 2020-12-23 | 2022-06-30 | 三井化学株式会社 | 培養部材およびその用途 |
RU2786587C2 (ru) * | 2018-03-30 | 2022-12-22 | Оризуру Терапьютикс, Инк. | Гетероциклическое соединение |
WO2023286772A1 (ja) * | 2021-07-12 | 2023-01-19 | 三菱ケミカル株式会社 | 心筋細胞の製造方法 |
WO2023074783A1 (ja) | 2021-10-28 | 2023-05-04 | 富士フイルム株式会社 | 心筋細胞層の製造方法、心筋細胞層、およびその利用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3221446B1 (en) * | 2014-11-17 | 2024-08-21 | Genome Research Limited | In vitro production of expanded potential stem cells |
WO2020125759A1 (zh) * | 2018-12-21 | 2020-06-25 | 汇瀚医疗科技有限公司 | 作为wnt信号通路抑制剂的化合物及其医学应用 |
CA3148370A1 (en) | 2019-08-23 | 2021-03-04 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
WO2021113382A1 (en) * | 2019-12-02 | 2021-06-10 | Cornell University | Compositions and methods for generation of sinoatrial node-like cells and their use in drug discovery |
JP7521738B2 (ja) * | 2020-05-18 | 2024-07-24 | キヤノン株式会社 | 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地 |
JP2023537923A (ja) | 2020-08-13 | 2023-09-06 | サナ バイオテクノロジー,インコーポレイテッド | 感作患者を低免疫原性細胞で処置する方法、ならびに関連する方法及び組成物 |
EP4347797A1 (en) | 2021-05-27 | 2024-04-10 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
EP4384188A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013111875A1 (ja) * | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
WO2014136519A1 (ja) * | 2013-03-08 | 2014-09-12 | 国立大学法人京都大学 | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
WO2015037706A1 (ja) * | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63190880A (ja) | 1986-09-09 | 1988-08-08 | Nippon Tokushu Noyaku Seizo Kk | 新規n−ベンゾチアゾリル−アミド類及び殺虫剤 |
US4970318A (en) | 1988-05-24 | 1990-11-13 | Pfizer Inc. | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
CN1217746A (zh) | 1996-04-29 | 1999-05-26 | 勒芬研究与发展公司 | 多能性兔胚胎干(es)细胞系及其在嵌合兔的产生中的应用 |
WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
BR0110428A (pt) | 2000-04-28 | 2003-06-17 | Sankyo Co | Composto ou um seu sal farmacologicamente aceitável, composição farmacêutica, usos de um composto ou um seu sal farmacologicamente aceitável, de um modulador de ppar gama e de um antagonista parcial, agentes que inibe a diferenciação de adipócitos, que acentua ou recupera a função osteogênica, para tratamento ou prevenção de osteoporose, que tem atividade moduladora de ppar gama, diminuidor do açúcar no sangue, para tratamento ou prevenção de diabetes melito, e, para tratamento ou prevenção |
US7425448B2 (en) | 2001-07-12 | 2008-09-16 | Geron Corporation | Cardiomyocyte precursors from human embryonic stem cells |
US7727762B2 (en) | 2003-10-03 | 2010-06-01 | Keiichi Fukuda | Method of inducing the differentiation of stem cells into myocardial cells |
US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
JP2005330443A (ja) | 2004-05-21 | 2005-12-02 | Fuji Photo Film Co Ltd | セルロース体組成物およびセルロース体フィルム |
EP1850840A2 (en) | 2005-01-13 | 2007-11-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
JP4701382B2 (ja) | 2005-02-09 | 2011-06-15 | 国立大学法人東京農工大学 | 心筋移植片の作製方法及び心筋分化促進剤 |
CN103055313A (zh) | 2005-07-07 | 2013-04-24 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
GB2447191B (en) | 2005-12-22 | 2011-08-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
JP2007252220A (ja) | 2006-03-20 | 2007-10-04 | Cardio Corp | 心筋細胞の製造方法および分化誘導剤 |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
CN101426902B (zh) | 2006-04-28 | 2013-03-27 | 第一三共株式会社 | 将多能性干细胞分化诱导成心肌细胞的方法 |
SG193653A1 (en) | 2007-03-23 | 2013-10-30 | Wisconsin Alumni Res Found | Somatic cell reprogramming |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US8603817B2 (en) | 2008-11-03 | 2013-12-10 | University Of Washington | Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling |
US20120115157A1 (en) | 2009-07-01 | 2012-05-10 | Trustees Of Dartmouth College | Methods for Screening for Antibiotic Compounds |
CN102648274B (zh) | 2009-12-09 | 2013-07-31 | 国立大学法人京都大学 | 包含双呋脒腙的促进多能干细胞分化成心肌细胞的组合物 |
WO2011127164A2 (en) | 2010-04-08 | 2011-10-13 | Fate Therapeutics, Inc. | Pharmaceutical compositions to treat fibrosis |
CN103209968B (zh) | 2010-08-26 | 2015-08-05 | 国立大学法人京都大学 | 多能干细胞心肌细胞分化促进剂 |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
SG11201500918YA (en) | 2012-08-07 | 2015-04-29 | Singapore Health Serv Pte Ltd | Method, combination and/or composition for inducing cardiomyocyte differentation |
-
2015
- 2015-05-29 EP EP15799980.6A patent/EP3150705B1/en active Active
- 2015-05-29 JP JP2016523588A patent/JP6651218B2/ja active Active
- 2015-05-29 WO PCT/JP2015/065643 patent/WO2015182765A1/ja active Application Filing
- 2015-05-29 US US15/314,409 patent/US10233426B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013111875A1 (ja) * | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
WO2014136519A1 (ja) * | 2013-03-08 | 2014-09-12 | 国立大学法人京都大学 | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
WO2015037706A1 (ja) * | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
Non-Patent Citations (11)
Title |
---|
HAKUNO, D. ET AL.: "Focal Adhesion Kinase Signaling Regulates Cardiogenesis of Embryonic Stem Cells", J. BIOL. CHEM., vol. 280, no. 47, 25 November 2005 (2005-11-25), pages 39534 - 39544, XP055240273, ISSN: 0021-9258 * |
KAZUSHIGE MINAMI ET AL.: "Shinki Teibunshi Kagobutsu o Mochiita Hito ES /iPS Saibo no Rinsho Grade Shinkin Bunka Yudoho no Kaihatsu", REGENERATIVE MEDICINE, vol. 12, 28 February 2013 (2013-02-28), pages 151, XP008181336 * |
MINAMI, I. ET AL.: "A Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions", CELL REPORTS, vol. 2, no. 5, 2012, pages 1448 - 1460, XP055097336, ISSN: 2211-1247 * |
RONCA, R. ET AL.: "Fibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells", J. CELL . MOL. MED., vol. 13, no. 8A, 2009, pages 1489 - 1498, XP055240270, ISSN: 1582-1838 * |
See also references of EP3150705A4 * |
SHEN, G. ET AL.: "A 2,6-Disubstituted 4- Anilinoquinazoline Derivative Facilitates Cardiomyogenesis of Embryonic Stem Cells", CHEMMEDCHEM, vol. 7, no. 4, 2012, pages 733 - 740, XP055240274, ISSN: 1860-7179 * |
TAKAYUKI MORISAKI: "Shinkin Bunka ni Okeru Bunshi Kaibogaku-teki Seigyo Kiko no Kaimei ni Kansuru Kenkyu", ANNUAL REPORT OF THE RESEARCH ON CARDIOVASCULAR DISEASES (HEISEI 15 NENDO, January 2005 (2005-01-01), pages 177, XP008181719 * |
VENTURA, C. ET AL.: "Protein Kinase C Signaling Transduces Endorphin-Primed Cardiogenesis in GTR1 Embryonic Stem Cells", CIRCULATION RESEARCH, vol. 92, no. 6, 2003, pages 617 - 622, XP002519846, ISSN: 1524-4571 * |
WANG, Z. ET AL.: "Neuregulin-1 enhances differentiation of cardiomyocytes from embryonic stem cells", MED. BIOL. ENG. COMPUT., vol. 47, no. 1, 2009, pages 41 - 48, XP019835287, ISSN: 1741-0444 * |
YUJI HARAGUCHI ET AL.: "Hito iPS Saibo no Fuyu Baiyoho Oyobi Shinkin Saibo eno Bunka Yudoho no Kento", REGENERATIVE MEDICINE, vol. 11, 1 June 2012 (2012-06-01), pages 211, XP008175720 * |
ZHOU, X. ET AL.: "Differentiation of nonbeating embryonic stem cells into beating cardiomyocytes is dependent on downregulation of PKCbeta and in concert with upregulation of PKCepsilon", DEVELOPMENTAL BIOLOGY, vol. 255, no. 2, 2003, pages 407 - 422, XP055240271, ISSN: 0012-1606 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431584A4 (en) * | 2016-03-18 | 2019-08-28 | Kyoto University | FREEZING METHOD FOR AGGREGATES OF MYOKARD CELLS DERIVED FROM PLURIPOTENTIAL STEM CELLS |
JPWO2017159862A1 (ja) * | 2016-03-18 | 2019-01-24 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
US12018280B2 (en) | 2016-03-18 | 2024-06-25 | Kyoto University | Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes |
WO2017159862A1 (ja) | 2016-03-18 | 2017-09-21 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
WO2018124210A1 (ja) * | 2016-12-28 | 2018-07-05 | 国立大学法人京都大学 | 環状心筋細胞塊 |
WO2019078278A1 (ja) | 2017-10-18 | 2019-04-25 | 国立大学法人京都大学 | 心筋細胞に分化させるための多能性幹細胞の製造方法 |
WO2019131806A1 (ja) | 2017-12-26 | 2019-07-04 | 株式会社マイオリッジ | 心筋細胞の薬剤応答性試験方法 |
WO2019189553A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 複素環化合物 |
CN111918866A (zh) * | 2018-03-30 | 2020-11-10 | 国立大学法人京都大学 | 杂环化合物 |
JPWO2019189553A1 (ja) * | 2018-03-30 | 2021-03-25 | 国立大学法人京都大学 | 複素環化合物 |
KR102708268B1 (ko) | 2018-03-30 | 2024-09-20 | 오리즈루 세라퓨틱스 가부시키가이샤 | 헤테로시클릭 화합물 |
JP7257698B2 (ja) | 2018-03-30 | 2023-04-14 | オリヅルセラピューティクス株式会社 | 複素環化合物 |
US11401264B2 (en) | 2018-03-30 | 2022-08-02 | Orizuru Therapeutics, Inc. | Heterocyclic compound |
RU2786587C2 (ru) * | 2018-03-30 | 2022-12-22 | Оризуру Терапьютикс, Инк. | Гетероциклическое соединение |
CN111918866B (zh) * | 2018-03-30 | 2023-07-04 | 千纸鹤治疗公司 | 杂环化合物 |
WO2020009188A1 (ja) | 2018-07-06 | 2020-01-09 | 株式会社マイオリッジ | 細胞シートの製造方法、心筋細胞シート、および心筋細胞シート製造用キット |
JP2021126066A (ja) * | 2020-02-12 | 2021-09-02 | 株式会社カネカ | 細胞凝集抑制剤 |
JP7477983B2 (ja) | 2020-02-12 | 2024-05-02 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2021251394A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社マイオリッジ | 向上した心筋細胞純度を有する心筋細胞集団の製造方法、心筋細胞の純化方法、心筋細胞集団、および移植材料 |
WO2021251393A1 (ja) | 2020-06-09 | 2021-12-16 | 株式会社マイオリッジ | 心筋細胞集団の製造方法、心筋細胞の増殖方法、心筋細胞集団、移植材料、多核心筋細胞、および心筋細胞増殖用キット |
WO2022014622A1 (ja) * | 2020-07-14 | 2022-01-20 | 株式会社カネカ | 心筋細胞塊の製造方法 |
WO2022138101A1 (ja) | 2020-12-23 | 2022-06-30 | 三井化学株式会社 | 培養部材およびその用途 |
WO2023286772A1 (ja) * | 2021-07-12 | 2023-01-19 | 三菱ケミカル株式会社 | 心筋細胞の製造方法 |
WO2023074783A1 (ja) | 2021-10-28 | 2023-05-04 | 富士フイルム株式会社 | 心筋細胞層の製造方法、心筋細胞層、およびその利用 |
Also Published As
Publication number | Publication date |
---|---|
EP3150705A4 (en) | 2017-12-13 |
JP6651218B2 (ja) | 2020-02-19 |
EP3150705B1 (en) | 2019-05-15 |
US10233426B2 (en) | 2019-03-19 |
JPWO2015182765A1 (ja) | 2017-04-20 |
US20170152485A1 (en) | 2017-06-01 |
EP3150705A1 (en) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6651218B2 (ja) | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 | |
JP6351567B2 (ja) | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 | |
JP6274510B2 (ja) | 多能性幹細胞の心筋分化誘導法 | |
JP5930205B2 (ja) | 多能性幹細胞の心筋分化促進剤 | |
US9499790B2 (en) | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | |
WO2017159862A1 (ja) | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 | |
WO2005007838A1 (ja) | 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株 | |
JP6333830B2 (ja) | 多能性幹細胞の心筋分化を促進する化合物 | |
US20220380724A1 (en) | Composition for promoting proliferation of stem cells, containing, as active ingredient, cp1p or pharmaceutically acceptable salt thereof | |
WO2023286772A1 (ja) | 心筋細胞の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15799980 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016523588 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15314409 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015799980 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015799980 Country of ref document: EP |